指南与共识急性肾损伤慢性肾脏病

EXTRIP工作组关于巴氯芬中毒体外治疗的推荐

Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning.
指南 / 共识 · Kidney Int · 2021-08-04

EXTRIP工作组基于43项研究(1项比较队列、1项汇总队列、1项药代动力学建模、40项病例报告或系列)系统综述了体外治疗在巴氯芬中毒中的作用。工作组认为巴氯芬在肾功能正常者中为「中度可透析」(证据质量C),在肾功能不全者为「可透析」(证据质量C)。建议急性巴氯芬中毒不进行体外治疗,而肾功能不全时治疗性巴氯芬中毒可考虑体外治疗,尤其昏迷需机械通气者。

要点

  • 急性巴氯芬中毒:不建议在标准治疗外进行体外治疗。
  • 肾功能不全时治疗性巴氯芬中毒:建议进行体外治疗,尤其昏迷需机械通气者。
  • 巴氯芬在肾功能正常者为中度可透析,肾功能不全者为可透析(证据质量C)。

核心结论

  • 急性巴氯芬中毒不建议在标准治疗外进行体外治疗。
  • 肾功能不全时治疗性巴氯芬中毒建议进行体外治疗,尤其昏迷需机械通气者。

研究设计与样本

  • EXTRIP工作组遵循EXTRIP方法,系统综述了43项研究:1项比较队列、1项汇总队列、1项药代动力学建模、40项病例报告或系列。

主要发现

  • 巴氯芬在肾功能正常者中为「中度可透析」(证据质量C),在肾功能不全者为「可透析」(证据质量C)。
  • 急性巴氯芬中毒25例和肾功能不全时治疗性巴氯芬中毒46例的临床数据中,未报告死亡或后遗症。
  • 急性巴氯芬中毒患者未发现体外治疗获益;间接证据提示体外治疗可能缩短肾功能不全时治疗性巴氯芬中毒的毒性脑病持续时间。

关键数值与推荐

  • 巴氯芬在肾功能正常者中为「中度可透析」(证据质量C),在肾功能不全者为「可透析」(证据质量C)。

临床怎么用

  • 急性巴氯芬中毒:在标准治疗(停药、呼吸支持、抗癫痫)基础上不进行体外治疗。
  • 肾功能不全时治疗性巴氯芬中毒:可考虑体外治疗,尤其昏迷需机械通气者,需权衡导管置入、操作及巴氯芬戒断等风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Baclofen toxicity results from intentional self-poisoning (acute baclofen poisoning) or accumulation of therapeutic dose in the setting of impaired kidney function. Standard care includes baclofen discontinuation, respiratory support and seizure treatment. Use of extracorporeal treatments (ECTRs) is controversial. To clarify this, a comprehensive review of the literature on the effect of ECTRs in baclofen toxicity was performed and recommendations following EXTRIP methods were formulated based on 43 studies (1 comparative cohort, 1 aggregate results cohort, 1 pharmacokinetic modeling, and 40 patient reports or series). Toxicokinetic data were available for 20 patients. Baclofen's dialyzability is limited by a high endogenous clearance and a short half-life in patients with normal kidney function. The workgroup assessed baclofen as "Moderately dialyzable" by intermittent hemodialysis for patients with normal kidney function (quality of evidence C) and "Dialyzable" for patients with impaired kidney function (quality of evidence C). Clinical data were available for 25 patients with acute baclofen poisoning and 46 patients with toxicity from therapeutic baclofen in kidney impairment. No deaths or sequelae were reported. Mortality in historical controls was rare. No benefit of ECTR was identified in patients with acute baclofen poisoning. Indirect evidence suggests a benefit of ECTR in reducing the duration of toxic encephalopathy from therapeutic baclofen in kidney impairment. These potential benefits were balanced against added costs and harms related to the insertion of a catheter, the procedure itself, and the potential of baclofen withdrawal. Thus, the EXTRIP workgroup suggests against performing ECTR in addition to standard care for acute baclofen poisoning and suggests performing ECTR in toxicity from therapeutic baclofen in kidney impairment, especially in the presence of coma requiring mechanical ventilation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Ghannoum M, Berling I, Lavergne V, et al. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. Kidney Int. 2021. PMID: 34358487. doi:10.1016/j.kint.2021.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。